Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted anticancer drug that is used to treat non-small cell lung cancer (NSCLC). Previous studies have confirmed that erlotinib is safe and is well-tolerated by patients. The most common adverse reactions observed following erlotinib treatment include a rash and mild diarrhea. In the current study, the first case of acute myocardial infarction following one month of treatment with erlotinib in a 63-year-old male NSCLC patient is presented. The present study highlights the importance of clinicians remaining cautious following erlotinib administration. In elderly NSCLC patients and those with a history of coronary heart disease, cardiac function must be carefully monitored following erlotinib treatment so that serious adverse reactions, such as myocardial infarction, may be identified early and treated quickly.
Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
Shanshan
S
Ding
Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
Fei
F
Long
Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.
Shujuan
S
Jiang
adverse reactions; erlotinib; lung cancer; myocardial infarction; targeted therapy